PT - JOURNAL ARTICLE AU - Manuela Di Fusco AU - Mary M Moran AU - Alejandro Cane AU - Daniel Curcio AU - Farid Khan AU - Deepa Malhotra AU - Andy Surinach AU - Amanda Miles AU - David Swerdlow AU - John M McLaughlin AU - Jennifer L Nguyen TI - Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2 AID - 10.1101/2021.10.12.21264707 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.12.21264707 4099 - http://medrxiv.org/content/early/2021/10/16/2021.10.12.21264707.short 4100 - http://medrxiv.org/content/early/2021/10/16/2021.10.12.21264707.full AB - Objective To evaluate COVID-19 vaccine breakthrough infections among immunocompromised (IC) individuals.Methods Individuals vaccinated with BNT162b2 were selected from the US HealthVerity database (12/10/2020-7/8/2021). COVID-19 vaccine breakthrough infections were examined in fully vaccinated (≥14 days after 2nd dose) IC individuals (IC cohort), 12 mutually exclusive IC condition groups, and a non-IC cohort. IC conditions were identified using an algorithm based on diagnosis codes and immunosuppressive (IS) medication usage.Results Of 1,277,747 individuals ≥16 years of age who received 2 BNT162b2 doses, 225,796 (17.7%) were identified as IC (median age: 58 years; 56.3% female). The most prevalent IC conditions were solid malignancy (32.0%), kidney disease (19.5%), and rheumatologic/inflammatory conditions (16.7%). Among the fully vaccinated IC and non-IC cohorts, a total of 978 breakthrough infections were observed during the study period; 124 (12.7%) resulted in hospitalization and 2 (0.2%) were inpatient deaths. IC individuals accounted for 38.2% (N=374) of all breakthrough infections, 59.7% (N=74) of all hospitalizations, and 100% (N=2) of inpatient deaths. The proportion with breakthrough infections was 3 times higher in the IC cohort compared to the non-IC cohort (N=374 [0.18%] vs. N=604 [0.06%]; unadjusted incidence rates were 0.89 and 0.34 per 100 person-years, respectively. Organ transplant recipients had the highest incidence rate; those with >1 IC condition, antimetabolite usage, primary immunodeficiencies, and hematologic malignancies also had higher incidence rates compared to the overall IC cohort. Incidence rates in older (≥65 years old) IC individuals were generally higher versus younger IC individuals (<65).Limitations This retrospective analysis relied on coding accuracy and had limited capture of COVID-19 vaccine receipt.Conclusions COVID-19 vaccine breakthrough infections are rare but are more common and severe in IC individuals. The findings from this large study support FDA authorization and CDC recommendations to offer a 3rd vaccine dose to increase protection among IC individuals.Competing Interest StatementDisclosure statement: M Di Fusco, MM Moran, A Cane, D Curcio, F Khan, D Malhotra, A Miles, D Swerdlow, J McLaughlin, and JL Nguyen are employees of Pfizer. A Surinach is an employee of Genesis Research, which has received consulting fees from Pfizer. Funding StatementThis study was sponsored by Pfizer Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was deemed exempt from Institutional Review Board (IRB) review pursuant to the terms of the US Department of Health and Human Service's Policy for Protection of Human Research Subjects at 45 C.F.R. 46.104(d); category 4 exemption (Sterling IRB, Boston, Maine waived ethical approval for this work).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData generated or analyzed during this study are available upon request.